New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareTesofensine vs ARA-290

Tesofensine vs ARA-290

Side-by-side comparison of key properties, dosing, and research.

Fat Loss & Metabolic
Tesofensine
Immune SupportRecovery & Repair
ARA-290
Summary
Tesofensine is a triple monoamine reuptake inhibitor (TMRI) that blocks reuptake of serotonin, dopamine, and norepinephrine. Originally developed for Alzheimer's and Parkinson's disease, it was repurposed as a potent weight loss agent after clinical trials demonstrated substantial fat loss via appetite suppression and increased energy expenditure.
ARA-290 is a synthetic 11-amino acid peptide derived from the helix B region of erythropoietin (EPO). Unlike EPO, it selectively activates the innate repair receptor (IRR) without stimulating hematopoiesis, providing tissue protection, anti-inflammation, and neuropathy relief.
Half-Life
8-10 days (exceptionally long; accumulates over weeks)
~2–4 hours (SC administration)
Admin Route
Oral
SubQ
Research
Typical Dose
0.25-0.5 mg per day
4 mg (fixed dose)
Frequency
Once daily
Once daily
Key Benefits
  • Potent appetite suppression via triple monoamine reuptake inhibition
  • Significant weight loss (8-12% body weight in phase II trials at 0.5 mg)
  • Increases basal metabolic rate and energy expenditure
  • Reduces fat mass preferentially over lean mass
  • Potential cognitive benefit via dopaminergic and noradrenergic enhancement
  • Longer half-life than sibutramine allows once-daily dosing
  • Reduces neuropathic pain from small fiber neuropathy
  • Anti-inflammatory without immune suppression
  • Tissue protection after ischemia/reperfusion injury
  • Promotes nerve fiber regeneration
  • Improves symptoms of sarcoidosis-associated neuropathy
  • May reduce insulin resistance and improve metabolic health
  • Shown to improve autonomic neuropathy symptoms
Side Effects
  • Elevated heart rate and blood pressure (sympathomimetic)
  • Dry mouth
  • Insomnia and sleep disturbances
  • Nausea
  • +4 more
  • Injection site reactions
  • Mild fatigue at initiation
  • Transient warm sensation post-injection
  • Rare: mild headache
Stacks With